Asian Currencies Edge Higher as Markets Look to Fed Rate Cut; Rupee Steadies Near Record Lows 
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
Australia’s Economic Growth Slows in Q3 Despite Strong Investment Activity 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
Asian Markets Mixed as RBI Cuts Rates and BOJ Signals Possible Hike 
Gold Prices Steady as Markets Await Key U.S. Data and Expected Fed Rate Cut 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
Dollar Slides to Five-Week Low as Asian Stocks Struggle and Markets Bet on Fed Rate Cut 
Dollar Holds Steady as Markets Shift Focus to 2026 Rate Cut Expectations 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
Citi Sets Bullish 2026 Target for STOXX 600 as Fiscal Support and Monetary Easing Boost Outlook 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
European Oil & Gas Stocks Face 2026 With Cautious Outlook Amid Valuation Pressure 
Europe Confronts Rising Competitive Pressure as China Accelerates Export-Led Growth 
Asia’s IPO Market Set for Strong Growth as China and India Drive Investor Diversification 
Samsung Biologics contradicted reports that it will be producing Pfizer’s coronavirus vaccine. There were news going around saying the South Korean biotechnology company headquartered in Incheon is set to start the production of the said American pharmaceutical corp’s COVID-19 vaccine soon.
False manufacturing deal report?
As per The Korea Herald, Samsung Biologics said that the report that was published by the Korea Economic Daily was “not factual.” In the report, it was claimed that the Korean firm is in talks with Pfizer for a manufacturing deal.
An unnamed source from the government allegedly said, “If all goes well, the company will be able to begin mass production of the vaccine in August at the earliest.”
However, Samsung Biologics is saying there is no such deal and not even a discussion about any contract to produce the vaccines for Pfizer. Besides, the American pharma company does not appear to have a problem in producing huge amounts of vaccine doses by itself.
In fact, Bloomberg reported just last week that Pfizer and BioNTech can produce as many as 3 billion doses of their coronavirus vaccine in this year alone. This is said to be more than double the number that the company’s partners had predicted six months ago.
What’s more, Pfizer and BioNTech are reportedly further increasing their production capacity for next year. They are aiming to manufacture more than 3 billion vials of the vaccine. The boost in production comes as the demand has also surged around the world.
Pfizer also deny production outside of its manufacturing lines
It was reported that Pfizer is exclusively manufacturing its own vaccine in its two dedicated supply lines located in Europe and the U.S. The doses made here are for global distribution.
“At this time, we are not in discussions for any additional manufacturing outside these established supply lines for this vaccine,” Pfizer said. “Once the pandemic supply phase is over and we enter a phase of regular supplies, Pfizer will certainly evaluate all additional opportunities available.”
Meanwhile, South Korea is one of the countries that are waiting for deliveries of Pfizer vaccines. It was said that the Korean government has a contract with the vaccine maker for the supply of 66 million doses of its COVID-19 vaccine.
